China: Food and Drugs Law

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

China Boosts Medical Innovation For Public Health

China will accelerate the development of core medical technologies and innovative drugs targeting common and complex diseases, including cardiovascular conditions...

China Healthcare

AC

AFD China

China’s Pharma Innovators Pursue A Range Of Deal Structures To Support Global Expansion

China has emerged as a global pharmaceutical innovation powerhouse, leveraging its scientific expertise, AI capabilities, and streamlined regulatory environment to accelerate drug development.

China Healthcare

AO

A&O Shearman

ライブ販売の商標侵害に厳罰山東高裁、懲罰的賠償で抑止強化

山東省高級人民法院（高裁）はこのほど、2025年の知的財産分野における懲罰的賠償の典型事例を公表した...

K

Kangxin

China | Market Exclusivity And Data Exclusivity Included In Drug Administration Law Revisions

Marking a milestone in China's drug regulatory landscape, the 2026 Revisions of China's Drug Administration Law introduce data exclusivity and market exclusivity into the regulatory framework...

China Healthcare

SF

Spruson & Ferguson

Interpretation Of The Revised 'Regulations For The Implementation Of The Drug Administration Law' And Compliance Implications

CT

Chang Tsi & Partners

China Life Sciences: 2025 Year In Review

China Healthcare

AP

Arnold & Porter

The Patent Term Compensation And Protection Scope In The Compensated Period For Drug Invention Patents

AC

AFD China

药品发明专利期限补偿及其间的保护范围

AC

AFD China

China On The Move: Key Takeaways From The 2025 NRDL Negotiations And Adjustment

China Healthcare

GT

Greenberg Traurig, LLP

2025年度广告合规洞察：监管新规下的合规之道

China Media & IT

FP

Fangda Partners

A Legal Commentary On The Latest Implementing Regulations Of The PRC Drug Administration Law

China Healthcare

FP

Fangda Partners

Thin Disclosure But "Bulletproof" Protection: How A Salt Form Patent Was Upheld In China Despite Minimal Data

EI

Eagle IP

商标不使用撤销制度中"不使用的正当理由"的内涵浅析

CP

CCPIT Patent & Trademark Law Office

如何为"已知物质"的新医药用途争取专利保护？ ——中国审查实务深度解析与策略指南

CP

CCPIT Patent & Trademark Law Office

JWC列明区域变化对CIF卖方的风险与应对 ——以海上运输为视角

China Transport

JT

Beijing Jincheng Tongda & Neal Law Firm

Inside Arbitration Issue 21: Perspectives On Cross-border Disputes

Worldwide Litigation

KL

Herbert Smith Freehills Kramer LLP

PRC Financial Regulation Annual Report (2026) FinTech

Worldwide Technology

FP

Fangda Partners

PRC Financial Regulation Annual Report (2026) General

FP

Fangda Partners

新《公司法》视野下股东出资加速到期与追加被执行人的法律实务分析

China Commercial

AB

AnJie Broad Law Firm

China Newsletter | Q3 2025/Issue No. 65

This China Newsletter provides an overview of key developments in the following areas...

GT

Greenberg Traurig, LLP

Extract Of Annual Report On Issues Of Law Application By Nationwide Courts In IP Cases (2024)

On April 21, 2025, the Supreme People's Court (SPC) released the Annual Report on the Issues of Law Application in intellectual property (IP) cases...

PP

Panawell & Partners

艾睿铂发布2026年全球消费者展望：经济不确定性将持续加深节俭趋势，重塑全球消费优先级

调研表明全球高收入人群及中国消费者正在削减支出

A

AlixPartners

Understanding China's Pharmaceuticals Patent Linkage System: Judicial Trends And Key Takeaways From Recent Cases (Part 2)

In the first article of this series, we elaborated on the regulatory framework of the Pharmaceuticals patent linkage system of China, along with the current status of case acceptance, applicable conditions...

CT

Chang Tsi & Partners

Ten Minefields: A Guide To Avoiding Pitfalls In Applying For Human Genetic Resources Projects In China

China Healthcare

HK

Han Kun Law Offices

China Released Draft Medical Device Law For Comments

China Healthcare

HK

Han Kun Law Offices

Understanding China's Pharmaceutical Patent Linkage System: Framework And Case Overview (Part 1)

CT

Chang Tsi & Partners

China Life Sciences Compliance Update: Insurance Fraud Enforcement Campaign And New Ethical Code For HCPs

China Healthcare

AP

Arnold & Porter

China Life Sciences Compliance Update: Kickback And Third-Party Case Study

China Healthcare

AP

Arnold & Porter

Starbucks Brews A New Chapter In China

MC

Marks & Clerk

以案说法：拆解申请香港资产冻结令协助内地民商事判决在港执行的条件

China Commercial

JT

Beijing Jincheng Tongda & Neal Law Firm

专利审查中引入跨领域知识作为公知常识的几点思考

CP

CCPIT Patent & Trademark Law Office

医药健康企业融资谈判过程中需要创始人注意的两三事（上篇）

China Healthcare

JT

Beijing Jincheng Tongda & Neal Law Firm

Understanding The EU's International Procurement Instrument

China Government

CM

Crowell & Moring LLP

以案说法：拆解申请香港资产冻结令协助内地民商事判决在港执行的条件

原告广西宏桂汇康食品有限公司（"广西宏桂"）是一家国有企业...

China Commercial

JT

Beijing Jincheng Tongda & Neal Law Firm

专利审查中引入跨领域知识作为公知常识的几点思考

在关于发明申请的专利实质审查实践中，审查员有时需要对最接近的现有技术和"本领域的公知常识"进行结合来评述创造性。当这种结合超越了发਴

CP

CCPIT Patent & Trademark Law Office

医药健康企业融资谈判过程中需要创始人注意的两三事（上篇）

近两年，因为生物医药类企业IPO承压...

China Healthcare

JT

Beijing Jincheng Tongda & Neal Law Firm

Understanding The EU's International Procurement Instrument

Earlier this year, the Commission relied for the first time on the EU's International Procurement Instrument in order to take measures against China for its failure to ensure reciprocal access to public...

China Government

CM

Crowell & Moring LLP

汉坤 • 观点 | 《药品管理法实施条例》（修订草案）重点快评

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Achievements Of Our Country's Drug Review And Approval System Reform (Part 1)

Since 2013, the Drug Evaluation Center of the State Medical Products Administration (hereinafter referred to as CDE) has released the annual drug review report of the previous year every year...

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of The "Detailed Rules For The Supervision Of Internet Diagnosis And Treatment (Trial)"

Since the General Office of the State Council issued the "Opinions on Promoting the Development of "Internet + Medical Health" on April 25...

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Finally Waiting For You - Interpreting The New Policy Of Cross-border Contract Production Of Drugs And Medical Devices In The Guangdong-Hong Kong-Macao Greater Bay Area

On June 29, 2022, the National Medical Products Administration ("NMPA") publicly released the "Implementation Plan for Supporting Hong Kong and Macao Drug Marketing Authorization Holders...

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Research On Urban Customized Commercial Medical Insurance

In order to promote the construction of a healthy China, our country has continuously strengthened the top-level design of the universal medical security system.

China Insurance

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Of Our Country's Drug Review And Approval System (Part II)

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Achievements Of Our Country's Drug Review And Approval System (Part II)

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 医药BD项目如何友好"分手"？

China Healthcare

HK

Han Kun Law Offices

How Digital Therapeutics (DTx) Products Are Regulated In China?

China Healthcare

HK

Han Kun Law Offices

生命科学行业License-in/out合同争议要点分析（三）：不竞争条款

China Healthcare

HK

Han Kun Law Offices

2024 Data Analytics: China Life Sciences NewCo & Licensing Terms

China Healthcare

HK

Han Kun Law Offices

Strengthening Oversight of Imported Drugs: Key Takeaways into New Regulations on Domestic Responsible Entities

China Healthcare

HK

Han Kun Law Offices

First Drug Patent Term Extension Granted In China

TM

Toby Mak

Han Kun • Opinion | Hainan Boao Lecheng Clinical Urgently Needs A Review Of The Highlights Of The New Regulations On The Management Of Imported Drugs And Devices

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Key Points For The Supervision Of Medical And Three-Product And One-Device Advertising Under The New Regulations On Internet Advertising

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | CAR-T/NK监管路在何方 — 体细胞临床研究工作指引（征求意见稿）要点解读

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Implementation And Regulation Of DCT (Decentralized Clinical Trials) In China

China Healthcare

HK

Han Kun Law Offices

Strategic Insights For The Localization Of Pharmaceutical And Medical Device Manufacturing In China

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | LDT试点新规解读

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | The Spring Of Traditional Chinese Medicine? From The "Special Provisions On The Registration And Administration Of Traditional Chinese Medicines", The Characteristic Marketing Evaluation System Of Traditional Chinese Medicine

China Healthcare

HK

Han Kun Law Offices

See more

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More